The Efficacy and Safety of Short-term Therapy with Itraconazole Melt-Extrusion Tablet in The Hyperkeratotic Type of Tinea Pedis and/or Tinea Manus.
- Author:
Kyung Sool KWON
1
;
Sang Tae KIM
;
Chul Hyun AHN
;
Jang Soo LEE
;
Ho Seok SUH
;
Chea Wook LEE
;
Jae Young LIM
;
Chang Keun OH
;
Ho Sun JANG
Author Information
1. Department of Dermatology, Pusan National University Hospital, Korea.
- Publication Type:Original Article
- Keywords:
Itraconazole melt-extrusion tablet;
Tinea pedis;
Tinea manus;
Short-term therapy
- MeSH:
Absorption;
Antifungal Agents;
Dermatology;
Female;
Follow-Up Studies;
Gastrointestinal Tract;
Hospitals, General;
Humans;
Itraconazole*;
Pruritus;
Tinea Pedis*;
Tinea*
- From:Korean Journal of Medical Mycology
2000;5(1):13-19
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The many antifungal agents have been used in fungal infections. In usual trial agents, itraconazole still remains difficult to absorption in gastrointestinal tract. OBJECTIVE: The purpose of this study is to evaluate the clinical efficacy and adverse reactions of short-term itraconazole melt-extrusion tablet increased in hyperkeratotic type of tinea pedis and/or tinea mauns. METHODS: From November 1998 to February 1999, a total of 60 patients with palmoplantar type of tinea pedis and/or tinea manus at Department of Dermatology of 5 general hospital, were enrolled in a subject group for the study. Itraconazole melt-extrusion tablet was administered, 200mg twice daily, in one week. Clinical symptoms and signs with mycological findings were assessed. RESULTS: Fifty-six patients (male 33, female 23; mean age 36.1+/-10.7; mean duration 6.5+/-4.8) completed the follow-ups. Direct KOH smear examination was positive in all them. Decrease in initial percentages of patients showing symptoms at the last follow-up 2 months after starting therapy: for scale, from 100% to 85.4%; for ertyema, from 91.1% to 10.7%; for hyperkeratosis from 100% to 32.3%; for pruritus, from 82.1% to 10.7%. Mycologic cure rate was 92.9% at the last follow-up. Overall clinical responses evaluated at the last follow-up were 'cured' in 6 pathients(10.7%), 'markedly improved' in 38 patiendts(67.9%), making a clinical response rate of 78.6%. During therapy, transient epigastria pain and indigeastion developed in 5 patients(8.9%). CONCLUSION: With these results, itraconazole melt-extrusion table is considered an effective and safe treatment modality for hyperkeratotic type of tinea pedis and/or tinea manus.
